Antitumoral effects of lipid A: Preclinical and clinical studies

Journal of Investigative Medicine

Volumn 50, Issue 3, 2002, Pages 173-178

  Pance, Alena ^a   Reisser, Danièle ^a   Jeannin, Jean François ^a  

^a PSL RESEARCH UNIVERSITY   (France)

Author keywords

Animal models; Clinical trials; Immunotherapy; Lipid A; Tumor

Indexed keywords

2 DEOXY 3 O (9 PHENYLNONANOYL) 2 [3 (9 PHENYLNONANOYLOXY)TETRADECANOYLAMINO]GLUCOPYRANOSE 4 SULFATE; BCG VACCINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; DT 5461; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; LIPID A; LIPID A DERIVATIVE; MELACINE; OM 174; ONCOVAX P; PHOSPHORYL LIPID A; SDZ MRL 953; THERATOPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; REVIEW; SIDE EFFECT; VACCINATION;

ANIMALIA; MYCOBACTERIUM BOVIS BCG;

EID: 0036098567     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2002.33430     Document Type: Review

References (48)

1. Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity
2. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors
3. Correlation between the capacity to activate macrophages in vitro and the antitumor activity in vivo of lipopolysaccharides from different bacterial species
4. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: Involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions
5. Antitumor mechanism of intradermal administration of lipopolysaccharide
6. Biological activities and antitumor effects of synthetic lipid A analog linked N-acylated serine
7. Involvement of T lymphocytes in curative effect of a new immunomodulator OM 163 on rat colon cancer metastases
8. Cure of colon cancer metastasis in rats with the new lipid A OM 174: Apoptosis of tumor cells and immunization of rats
9. Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-β1 in tumor cells: Implications for tumor development
10. The treatment of inoperable sarcoma with the mixed toxins of Erysipelas and bacillus prodigiosus
11. Chemical treatment of tumors: V. Isolation of the hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate
12. Similarities of the anti-tumor actions of endotoxin, lipid A and double-stranded RNA
13. Mechanisms of the antitumoral effect of lipid A
14. Intratumoral necrosis factor induction and tumor growth suppression by ONO-4007, a low-toxicity lipid A analog
15. Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat
16. Systemic administration of a synthetic lipid A derivative, DT-5461a, reduces tumor blood flow through endogenous TNF production in hepatic cancer model of VX2 carcinoma in rabbits
17. Therapeutic effect of a new synthetic lipid A analog (ONO-4007) on a tumor implanted at different sites in rats
18. DT-5461a, an antitumor synthetic lipid a analog, causes selective blood flow reduction in tumor tissue
19. ONO-4007 induces specific anti-tumor immunity mediated by tumor necrosis factor-α
20. Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats
21. Phase-I study of intravenous modified lipid A
22. Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients
23. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide
24. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate
25. Immunopharmacological activities of the nontoxic monophosphoryl lipid A of Porphyromonas gingivalis
26. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant
27. Active specific immunotherapy of melanoma with allogeneic cell lysates: Rationale, results, and possible mechanisms of action
28. Interim results of a Phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma
29. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma
30. M2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
31. Effect of Detox as an adjuvant for melanoma vaccine
32. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn
33. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients
34. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant
35. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant
36. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis
37. A randomised Phase II study of sialyl-Tn and Detox-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer
38. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine
39. Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide
40. + lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy
41. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients
42. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide
43. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine
44. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and Theratope STn-KLH cancer vaccine
45. Active specific immunotherapy for metastatic colorectal carcinoma: Phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 α
46. A Phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors
47. Immunologic approaches to the treatment of prostate cancer
48. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer